4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design
Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolid...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/23/21/13135 |
| _version_ | 1797467897191202816 |
|---|---|
| author | Piotr Roszczenko Serhii Holota Olga Klaudia Szewczyk Rostyslav Dudchak Krzysztof Bielawski Anna Bielawska Roman Lesyk |
| author_facet | Piotr Roszczenko Serhii Holota Olga Klaudia Szewczyk Rostyslav Dudchak Krzysztof Bielawski Anna Bielawska Roman Lesyk |
| author_sort | Piotr Roszczenko |
| collection | DOAJ |
| description | Oncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolidinone-bearing hybrid molecules with potential anticancer activity reported during the period from the years 2017–2022 are summarized. The main emphasis is on the application of molecular hybridization methodologies and strategies in the design of small molecules as anticancer agents. Based on the analyzed data, it was observed that the main directions in this field are the hybridization of scaffolds, the hybrid-pharmacophore approach, and the analogue-based drug design of 4-thiazolidinone cores with early approved drugs, natural compounds, and privileged heterocyclic scaffolds. The mentioned design approaches are effective tools/sources for the generation of hit/lead compounds with anticancer activity and will be relevant to future studies. |
| first_indexed | 2024-03-09T19:00:16Z |
| format | Article |
| id | doaj.art-13d3ef13e17b485497048fc752fd242a |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-09T19:00:16Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-13d3ef13e17b485497048fc752fd242a2023-11-24T05:03:04ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672022-10-0123211313510.3390/ijms2321131354-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug DesignPiotr Roszczenko0Serhii Holota1Olga Klaudia Szewczyk2Rostyslav Dudchak3Krzysztof Bielawski4Anna Bielawska5Roman Lesyk6Department of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, PolandDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, UkraineDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, PolandDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, PolandDepartment of Synthesis and Technology of Drugs, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, PolandDepartment of Biotechnology, Medical University of Bialystok, Kilinskiego 1, 15-089 Bialystok, PolandDepartment of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, UkraineOncological diseases have currently reached an epidemic scale, especially in industrialized countries. Such a situation has prompted complex studies in medicinal chemistry focused on the research and development of novel effective anticancer drugs. In this review, the data concerning new 4-thiazolidinone-bearing hybrid molecules with potential anticancer activity reported during the period from the years 2017–2022 are summarized. The main emphasis is on the application of molecular hybridization methodologies and strategies in the design of small molecules as anticancer agents. Based on the analyzed data, it was observed that the main directions in this field are the hybridization of scaffolds, the hybrid-pharmacophore approach, and the analogue-based drug design of 4-thiazolidinone cores with early approved drugs, natural compounds, and privileged heterocyclic scaffolds. The mentioned design approaches are effective tools/sources for the generation of hit/lead compounds with anticancer activity and will be relevant to future studies.https://www.mdpi.com/1422-0067/23/21/13135molecular hybridizationhybrid molecules4-thiazolidinoneapproved drugsnatural compoundsprivileged heterocycles |
| spellingShingle | Piotr Roszczenko Serhii Holota Olga Klaudia Szewczyk Rostyslav Dudchak Krzysztof Bielawski Anna Bielawska Roman Lesyk 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design International Journal of Molecular Sciences molecular hybridization hybrid molecules 4-thiazolidinone approved drugs natural compounds privileged heterocycles |
| title | 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design |
| title_full | 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design |
| title_fullStr | 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design |
| title_full_unstemmed | 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design |
| title_short | 4-Thiazolidinone-Bearing Hybrid Molecules in Anticancer Drug Design |
| title_sort | 4 thiazolidinone bearing hybrid molecules in anticancer drug design |
| topic | molecular hybridization hybrid molecules 4-thiazolidinone approved drugs natural compounds privileged heterocycles |
| url | https://www.mdpi.com/1422-0067/23/21/13135 |
| work_keys_str_mv | AT piotrroszczenko 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT serhiiholota 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT olgaklaudiaszewczyk 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT rostyslavdudchak 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT krzysztofbielawski 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT annabielawska 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign AT romanlesyk 4thiazolidinonebearinghybridmoleculesinanticancerdrugdesign |